Site Search

... from patients to identify and evaluate cancer biomarkers. Testing patients for specific biomarkers is integral to precision medicine in cancer care, but despite evidence pointing to the clinical benefits associated with biomarker testing, routine clinical use does not always follow, and ... insurance would not cover it or their out-of-pocket costs would be too high. A new report by ACS CAN and LUNGevity Foundation found while health insurance coverage for biomarker testing has improved since the organizations’ last report in 2018, coverage is still failing to keep up ... a combination of factors, as highlighted in the ACS CAN report  Improving Access to Biomarker Testing - Advancing Precision Medicine in Cancer Care  which explores the current landscape of cancer biomarker testing, sheds light on the nature of challenges limiting adoption of appropriate ...